Find 43 companies with promising cash flow potential yet trading below their fair value.
To own Novanta, you need to believe in its role as a core technology supplier to medical, life science and advanced industrial OEMs, with earnings eventually catching up to a relatively high valuation. The Zacks Rank upgrade, tied to improving earnings estimates, supports that thesis but does not materially change the key near term catalyst, which remains execution on acquisitions, or the main risk around flat organic growth and integration of new assets.
The most relevant recent development here is the upcoming CJS Securities New Ideas Summer Conference appearance by Novanta’s CFO and COO, which gives investors a timely window into how management is thinking about earnings quality, acquisition integration and margin improvement. In the context of an earnings focused analyst upgrade, hearing directly from the executives who allocate capital and run operations could help you better weigh the upside from acquisitions against the risks of muted organic demand and ongoing restructuring costs.
However, investors should also be aware that higher leverage and integration complexity could amplify the impact of any stumble in acquisition driven growth...
Read the full narrative on Novanta (it's free!)
Novanta's narrative projects $1.2 billion revenue and $222.2 million earnings by 2029.
Uncover how Novanta's forecasts yield a $175.00 fair value, a 9% upside to its current price.
Three Simply Wall St Community fair value estimates for Novanta span roughly US$104 to US$175 per share, showing a wide spread of opinion. You should weigh these against the reliance on acquisitions for near term growth, and consider how different assumptions about integration risk can lead to very different views on the company’s potential.
Explore 3 other fair value estimates on Novanta - why the stock might be worth 35% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com